BLASINGLE-USEVIALPriority Review
Approved
Nov 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
Priority Review
TYSABRI (natalizumab) by Biogen is integrin receptor antagonists [moa]. First approved in 2004.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TYSABRI (natalizumab) is a monoclonal antibody integrin receptor antagonist administered intravenously for the treatment of multiple sclerosis and Crohn's disease. It works by blocking cell adhesion molecules that mediate immune cell infiltration into the central nervous system and gastrointestinal tract. The drug represents a targeted immunomodulatory approach to managing inflammatory conditions.
$40MPart D
LOE ApproachingProduct approaching loss of exclusivity with modest Part D spending (~$40M) and limited claim volume (~4,627 annually), signaling a mature, declining franchise requiring defensive commercial strategies.
Mechanism of Action
Integrin Receptor Antagonists
Pharmacologic Class:
Integrin Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)
Started Jul 2023
10 enrolled
Sickle Cell Disease
A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)
Started Jun 2023
400 enrolled
Multiple Sclerosis
A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple Sclerosis (MS) Participants
Started Feb 2023
34 enrolled
Multiple Sclerosis
A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Started Jan 2023
1 enrolled
Multiple Sclerosis, Relapsing-Remitting
Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)
Started Dec 2022
40 enrolled
Multiple SclerosisClinically Isolated Syndrome of Demyelination
Worked on TYSABRI at Biogen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.